Tempus
Precision Medicine & Genomics
Tempus AI applies artificial intelligence to clinical and molecular data to advance precision medicine, helping physicians make data-driven decisions for personalized patient care.
About Tempus
Tempus uses data and AI to create precision medicine services, including diagnostics for oncology, cardiology, radiology, and more.
Mission & Approach
AI Approach
predictive analytics, machine learning on multimodal clinical and genomic data
Products & Solutions
Tempus Platform
FlagshipplatformAI-enabled precision medicine platform for oncology and other diseases
Tempus builds AI-enabled precision medicine solutions that analyze clinical and molecular data to help physicians make real-time, data-driven decisions for patients. The platform integrates genomic sequencing, clinical data, and AI to provide personalized treatment recommendations across oncology and other therapeutic areas.
Hiring Activity
Product & Market
Product Stage
enterprisePrimary Market
providersCompany Details
- Founded
- 2015
- Headquarters
- Chicago, IL, USA
- Employees
- 3000
- Stage
- public
- Profile last updated
- June 22, 2026
Category
Precision Medicine & GenomicsWork here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSocial & Media
Follow on
Tempus in the News
All News →
What Healthcare AI Can Learn From Vertical AI in Construction
The health AI industry's most durable companies will be those that go deepest in a single clinical domain — not the ones that build the most general-purpose platform. The success of vertical AI in adjacent industries offers a clear template.
Tempus AI Reports 75% Revenue Growth in Q1 2026, Driven by Genomics and Data Licensing
Tempus AI has reported first-quarter 2026 revenue of $255 million, a 75% increase year-over-year, driven by strong growth in its genomics testing and data licensing segments as the company continues its post-IPO expansion.
Aidoc Raises $150 Million Series E Led by Goldman Sachs to Scale Clinical Foundation Model
Aidoc has closed a $150 million Series E round led by Goldman Sachs, with participation from existing investors, to scale its CARE clinical AI foundation model and expand its presence in radiology and emergency medicine workflows globally.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as employee counts and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.